Editorial

Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options

Tomas Hrncir

The Institute of Microbiology, The Czech Academy of Sciences, 549 22 Novy Hradek, Czech Republic; hrcir@biomed.cas.cz

The global incidence of numerous immune-mediated, metabolic, neurodegenerative, and psychiatric diseases is steadily increasing [1–3]. The increased morbidity of human populations makes them more vulnerable to additional burdens, including infectious diseases. For example, the mortality rate of diabetics infected with the original variant of the SARS Co-2 virus was about twice that of the general population [4,5]. It is becoming increasingly clear that the gut microbiota plays an important role in the development of many, if not all, of these diseases [2,6,7]. Many of these diseases, including COVID-19 infection [8], are associated with alterations in gut microbiota composition and function, i.e., dysbiosis [9,10]. The most typical features of dysbiosis are a decrease in the diversity of the microbiota, a loss of beneficial microbiota, or an overgrowth of harmful microbiota. The term “gut microbiota” includes all microorganisms, i.e., not only bacteria, but also fungi, protists, archaea, and viruses that live in the gastrointestinal tract. The focus of this Special Issue was on all possible triggers of gut microbiota dysbiosis [11] and exploring ways to restore the gut microbiota, such as dietary interventions [12–14], probiotics, and FMT, to identify disease-associated microbiota signatures, elucidate pathogenetic mechanisms [15], find new diagnostic and prognostic markers, and develop novel and promising microbiota-based treatments.

Dysbiosis can be caused by host-specific factors such as genetic background, health status (infections, inflammation), and lifestyle habits or—more importantly—environmental factors such as diet (high sugar, low fibre), xenobiotics (antibiotics, drugs, food additives), and hygiene.

Profound changes in the gut bacterial and fungal microbiota can be rapidly achieved by changes in macronutrients. These changes have significant physiological consequences as, for example, diets rich in simple sugars disrupt the intestinal barrier, trigger intestinal inflammation, and negatively affect host metabolism. However, in most cases, interactions between diet and microbiota are necessary for these deleterious effects, as they do not occur in the absence of the gut microbiota, i.e., in a germ-free state, and transplantation of the gut microbiota often results in transfer of the disease phenotype [16–18].

The effect of food additives on the gut microbiota has long been overlooked, but recently, several groups, including ours, have published data showing that some human gut microbiota are very sensitive to preservatives [10] and, also, that exposure to common food preservatives promotes overgrowth of proteobacteria [19]. Other categories of additives have also been shown to have negative effects on human health. For example, dietary emulsifiers directly alter the composition of the human gut microbiota and trigger intestinal inflammation [20]. Artificial sweeteners, such as Splenda, promote proteobacterial dysbiosis and exacerbate ileitis in SAMP1/ YitFc (SAMP) mice [21]. Paradoxically, non-caloric artificial sweeteners were introduced primarily to prevent metabolic syndrome, but unfortunately, they induce dysbiosis and promote glucose intolerance in a microbiota-dependent manner, leading to the negative metabolic effects that they were intended to prevent [22].

Host-derived factors that alter the burden and composition of the gut microbiota include bactericidal fluids produced by the gastric glands and liver, i.e., gastric acid and...
bile, and antimicrobial molecules such as defensins, lysozymes, and antibacterial lectins (Reg3γ) produced by Paneth cells, or SlgA produced by plasma cells [23]. Many infectious diseases, even if they are not gastrointestinal, trigger dysbiosis of the gut microbiota. Interestingly, SARS-CoV-2 infection has also been associated with dysbiosis of the gut microbiota [8]. Possible mechanisms that have been proposed include leakage of SARS-CoV-2 into the gut, direct binding of the virus to angiotensin-converting enzyme 2 (ACE2) receptors expressed on the surface of enterocytes, and circulating cytokines. COVID-19-associated dysbiosis has also been linked to increased intestinal permeability, which may negatively impact disease prognosis [24].

Disruption of the gut microbiota ecosystem has many consequences, which can be divided into disruption of the gut barrier and imbalance of the host immune and metabolic systems. The integrity of the intestinal wall could be compromised by acetaldehyde produced by the microbiota from exogenous or endogenous ethanol [25], direct mucolytic activity [26], and other mechanisms. The host immune system can be modulated by microbiota-derived molecules via inflammasome signalling or Toll-like receptor (TLR) and NOD-like receptor (NLR) signalling. Another mechanism is a shift in the balance between regulatory and proinflammatory immune cells. Effects on the host metabolic system, particularly glucose and lipid metabolism, are mediated by changes in bile acid composition, production of short-chain fatty acids (SCFAs) from dietary fibre, conversion of choline to trimethylamine (TMA), and many others [27].

Improved understanding of the gut microbiota, its metabolites, and its interactions with hosts could be used to develop new diagnostic and therapeautic approaches. Invasive diagnostic methods, such as tissue biopsy, are often required to make a diagnosis, determine disease subtype, and monitor disease progression and treatment efficacy. Therefore, non-invasive and reliable markers are needed. Recent research suggests that some members of the gut microbiota and metabolites may be useful as diagnostic and prognostic markers. For example, Loomba et al. found that a panel of the gut microbiota consisting of 37 bacterial strains can be used to accurately diagnose advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) [28] and Lee et al. found a strong association of Veillonellaceae with liver fibrosis in non-obese NAFLD patients and propose *Veillonellaceae* as a diagnostic marker [29]. Many gastrointestinal [30,31] and metabolic diseases [32–35] are associated with decreased levels of *Faecalibacterium prausnitzii*, which is considered a beneficial microbe due to its anti-inflammatory properties [33]. Another strain, *Bacteroides vulgatus*, is elevated in advanced fibrosis [28] and severe obesity [35]. Interestingly, cirrhotic patients often have a greater amount of oral microbial strains in the gut microbiome, such as *Prevotella*, *Veillonella*, and *Streptococcus* [32], which are generally absent in healthy individuals. Alterations in the fungal microbiota, characterised by a decrease in diversity and excessive growth of *Candida* [36], are common in patients with alcoholic liver disease. The most consistent finding in patients with IBD is a decreased diversity of the microbiota, characterised mainly by a decrease in the relative abundance of the Firmicutes phylum and an increase in the Proteobacteria phylum [37,38]. At the species level, a decrease in SCFA-producing bacteria such as *Faecalibacterium prausnitzii* and *Clostridium* clusters IV, XIVa and XVIII [39] and an increase in sulphate-reducing bacteria (SRB) such as *Desulfovibrio* [40,41], an increase in mucolytic bacteria such as *Ruminococcus gnavus* and *Ruminococcus torques* [26], and an imbalance of inflammatory and anti-inflammatory species have been demonstrated [37].

There are several microbiota-derived metabolites that could be used as biomarkers for disease. Some examples of promising metabolites used for the detection of liver diseases are succinate, phenylacetic acid, and 3-(4-hydroxyphenyl)-lactate. The 3-(4-hydroxyphenyl)-lactate, a product of aromatic amino acid metabolism, has been associated with liver fibrosis [42]; serum levels of phenylacetic acid correlate with the severity of hepatic steatosis [43]; and succinate produced by NAFLD-associated microbes such as *Bacteroidaceae* and *Prevotella* [44] was found to be elevated in faecal, serum, and liver samples from NAFLD patients [27].
The gut microbiota could be used for therapeutic purposes on several levels. First, the entire microbiota community could be restored by faecal microbiota transplantation (FMT). Second, individual strains or collections of beneficial strains (probiotics) could be introduced into the gut microbiota to supplement missing functions, whereas harmful or undesirable strains could be removed using antibiotics, antifungals, or bacteriophages. Finally, microbial metabolic pathways could be targeted to reduce or block the production of harmful metabolites or stimulate the production of beneficial metabolites.

FMT is a highly effective and life-saving therapy for recurrent *Clostridioides difficile* infections (rCDI), with cure rates exceeding 90%. It is often recommended as initial treatment because most CDI patients recover after a single FMT treatment [45]. However, the pharmaceutical industry is pushing to classify FMT as a drug to gain market exclusivity [46,47]. FMT has also been used experimentally to treat other gastrointestinal disorders, such as ulcerative colitis [48], constipation [49], irritable bowel syndrome [50], liver diseases such as cirrhosis with encephalopathy [51] and alcoholic hepatitis [52], and also neurological diseases such as multiple sclerosis [53] and Parkinson’s disease [54].

Probiotics are very popular agents for modulating gut microbiota and host health. Probiotic microorganisms exert their effects in several ways that often work together. The main mechanisms are modulation of the immune system, resistance to colonisation, improvement of the intestinal barrier, and production of metabolites that act locally (antimicrobials, enzymes, organic acids) and remotely (neurochemicals, hormones). There are compelling data on the safety and efficacy of several probiotics, including *Lactobacillus* spp., *Bifidobacterium* spp., and *Saccharomyces* spp. Other promising candidates include *Roseburia* spp. and *Faecalibacterium* spp. [55]. Probiotics have been successfully used to treat various diseases, including necrotising colitis [56], antibiotic-induced diarrhoea [57], ulcerative colitis [58], irritable bowel syndrome [59], and acute diarrhoea [60]. There is also evidence that orally administered probiotics may be beneficial in the treatment of metabolic, cardiovascular, or neurological diseases. However, high-quality randomised controlled clinical trials are needed to better understand which strains, formulations, and dosing patterns are effective for which conditions. In addition, probiotic interventions need to be individualised based on various host factors such as diet, baseline microbiota, genetics, disease subtype, or medications.

Therapeutic approaches that aim to manipulate the microbiota to increase the production of protective metabolites or block or decrease the production of harmful metabolites are also promising. For example, 3,3-dimethyl-1-butanol, a structural analogue of choline, has been successfully used to block the microbial conversion of dietary choline to TMA [61]. Trimethylamine N-oxide (TMAO), an oxidation product of TMA, has been associated with atherosclerosis and severe cardiovascular disease [62,63]. Interestingly, a recent study suggests that TMA and not TMAO may be the main culprit due to its nephrotoxicity and cardiotoxicity [64]. Manipulating the microbiota to increase SCFA production may also be helpful, as preclinical data show that SCFA supplementation improves hepatic steatosis. For example, supplementation of tributyrin, a butyrate prodrug, protected mice from obesity, insulin resistance, and hepatic steatosis [65], while supplementation of acetate and propionate prevented diet-induced weight gain, hepatic steatosis, and insulin resistance [66]. Other promising therapeutic targets include farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5 (TGR5) signalling pathways that modulate bile acid metabolism. For example, obeticholic acid, a potent activator of FXR, ameliorates hepatic steatosis, fibrosis, and portal hypertension in animal models of fatty liver disease [67–69] and treatment of adult NASH patients improved histological features [70]. In addition, NGM282, an analogue of fibroblast growth factor 19 (FGF19), i.e., a hormone that regulates bile acid synthesis and glucose homeostasis, has been shown to reduce hepatic steatosis in NASH patients [71].

In summary, there is growing evidence that the gut microbiota plays a critical role in many immune-mediated, metabolic, and neurological diseases. The most important factors that negatively affect the gut microbiota are environmental factors, particularly
unhealthy diets and medications. Genetic factors probably do not play as large a role in the increase in these diseases because they are relatively stable. A dysbiotic microbiota can compromise the gut barrier, resulting in tissues and organs being flooded with molecules from the diet and microbiota that can negatively impact the host immune system and metabolism. Moreover, the negative feedback loop can actually exacerbate dysbiosis. For example, the diseased liver is unable to regulate the gut microbiota through bile acids and other microbiota-modulating factors.

Several clinical studies have uncovered promising disease-associated microbiota signatures that could be used to detect early disease stages, monitor disease progression, and evaluate therapeutic efficacy. The diagnostic and prognostic value of microbiota signatures could be further enhanced by integration with the detection of microbiota-derived molecules in blood, urine, or faeces.

A detailed understanding of microbiota-host interactions will also enable the development of efficient microbiota-based therapies. These include manipulating the composition of the microbiota, e.g., introducing new beneficial strains or eliminating harmful strains, or replacing the entire ecosystem by transplanting the faecal microbiota. A complementary approach is based on the use of microbial metabolites, i.e., inducing or blocking the production of specific metabolites.

Whether dysbiosis of the gut microbiota is a direct cause of disease or merely reflects disease-induced changes in the host immune and metabolic systems remains unclear, but there are several examples of changes in the gut microbiota that precede the onset of disease, such as in type 1 diabetes [72] and Parkinson’s disease [73], and the body of evidence in support of a central role of the gut microbiota in the pathogenesis of many immune-mediated, metabolic, and neurological diseases continues to grow.

**Funding:** The author is funded by the Czech Science Foundation (20-09732S and 22-12533S) and the Institutional Research Concept (RVO: 61388971).

**Acknowledgments:** I would like to thank all the reviewers for their time and effort invested in improving the authors’ contributions and the staff of the *Microorganisms* Editorial Office for their excellent support in preparing the Special Issue.

**Conflicts of Interest:** The author declares that he has no conflict of interest.

**References**

1. Dinse, G.E.; Parks, C.G.; Weinberg, C.R.; Co, C.A.; Wilkerson, J.; Zeldin, D.C.; Chan, E.K.L.; Miller, F.W. Increasing Prevalence of Antinuclear Antibodies in the United States. *Arthritis Rheumatol.* 2020, 72, 1026–1035. [CrossRef] [PubMed]
2. GBD 2017 US Neurological Disorders Collaborators; Feigin, V.L.; Vos, T.; Alahdab, F.; Amit, A.M.L.; Bärnighausen, T.W.; Beghi, E.; Beheshti, M.; Chavan, P.P.; Criqui, M.H.; et al. Burden of Neurological Disorders Across the US From 1990–2017: A Global Burden of Disease Study. *JAMA Neurol.* 2021, 78, 165–176. [CrossRef]
3. Saklayen, M.G. The Global Epidemic of the Metabolic Syndrome. *Curr. Hypertens. Rep.* 2018, 20, 12. [CrossRef] [PubMed]
4. Kumar, A.; Arora, A.; Sharma, P.; Anikhindhi, S.A.; Bansal, N.; Singla, V.; Khare, S.; Srivastava, A. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes Metab. Syndr.* 2020, 14, 535-545. [CrossRef]
5. Huang, I.; Lim, M.A.; Pranata, R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia—A systematic review, meta-analysis, and meta-regression. *Diabetes Metab. Syndr.* 2020, 14, 395–403. [CrossRef]
6. Fan, Y.; Federsen, O. Gut microbiota in human metabolic health and disease. *Nat. Rev. Microbiol.* 2021, 19, 55–71. [CrossRef]
7. Hrncir, T.; Hrncirova, L.; Kverka, M.; Tlaskalova-Hogenova, H. The role of gut microbiota in intestinal and liver diseases. *Lab. Anim.* 2019, 53, 271–280. [CrossRef]
8. Yeoh, Y.K.; Zuo, T.; Lui, G.C.; Zhang, F.; Liu, Q.; Li, A.Y.; Chung, A.C.; Cheung, C.P.; Tso, E.Y.; Fung, K.S.; et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. *Gut* 2021, 70, 698–706. [CrossRef]
9. Levy, M.; Kolodziejczyk, A.A.; Thaiss, C.A.; Elinav, E. Dysbiosis and the immune system. *Nat. Rev. Immunol.* 2017, 17, 219–232. [CrossRef]
10. Hrncirova, L.; Machova, V.; Trckova, E.; Krejsek, J.; Hrncir, T. Food preservatives induce Proteobacteria dysbiosis in human-microbiota associated Nod2-deficient mice. *Microorganisms* 2019, 7, 383. [CrossRef]
11. Afridi, O.K.; Ali, J.; Chang, J.H. Fecal Microbiome and Resistome Profiling of Healthy and Diseased Pakistani Individuals Using Next-Generation Sequencing. *Microorganisms* 2021, 9, 616. [CrossRef] [PubMed]
12. van der Merwe, M.; Moore, D.; Hill, J.L.; Keating, F.H.; Buddington, R.K.; Bloomer, R.J.; Wang, A.; Bowman, D.D. The Impact of a Dried Fruit and Vegetable Supplement and Fiber Rich Shake on Gut and Health Parameters in Female Healthcare Workers: A Placebo-Controlled, Double-Blind, Randomized Clinical Trial. *Microorganisms* 2021, 9, 843. [CrossRef] [PubMed]

13. Shahinoozaman, M.; Raychaudhuri, S.; Fan, S.; Obanda, D.N. Kale Attenuates Inflammation and Modulates Gut Microbial Composition and Function in C57BL/6j Mice with Diet-Induced Obesity. *Microorganisms* 2021, 9, 238. [CrossRef] [PubMed]

14. Kohlert, E.; Kreutz, C.; Binder, N.; Hannibal, L.; Gorkiewicz, G.; Müller, A.; Storz, M.A.; Huber, R.; Lederer, A.K. Changes in Gut Microbiota after a Four-Week Intervention with Vegan vs. Meat-Rich Diets in Healthy Participants: A Randomized Controlled Trial. *Microorganisms* 2021, 9, 727. [CrossRef]

15. Hrnčirová, T.; Hrnčirova, L.; Kverka, M.; Hromadka, R.; Machova, V.; Trckova, E.; Kostovcikova, K.; Kralickova, P.; Krejsek, J.; Tlaskalova-Hogenova, H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. *Microorganisms* 2021, 10, 957. [CrossRef]

16. Vrieze, A.; Van Noord, E.; Holleman, F.; Salojiärvi, J.; Kootte, R.S.; Bartelsman, J.F.; Dallinga-Thie, G.M.; Ackermans, M.T.; Serlie, M.J.; Oozeer, R.; et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology* 2021, 143, 913–916. [CrossRef]

17. Schulz, M.D.; Atay, C.; Heriting, J.; Romrig, F.K.; Schwitalla, S.; Aydin, B.; Ziegler, P.K.; Varga, J.; Reindl, W.; Pommerenke, C.; et al. High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. *Nature* 2014, 514, 508–512. [CrossRef]

18. Collins, S.M.; Kassam, Z.; Bercik, P. The adoptive transfer of behavioural phenotype via the intestinal microbiota: Experimental evidence and clinical implications. *Curr. Opin. Microbiol.* 2013, 16, 240–245. [CrossRef]

19. Hrnčirová, L.; Hudcovic, T.; Sukova, E.; Machova, V.; Trckova, E.; Krejsek, J.; Hrnčir, T. Human gut microbes are susceptible to antimicrobial food additives in vitro. *Folia Microbiol. (Praha)* 2019, 64, 497–508. [CrossRef]

20. Chassaing, B.; Van de Wiele, T.; De Bodt, J.; Marzorati, M.; Gewirtz, A.T. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. *Gut* 2017, 66, 1414–1427. [CrossRef]

21. Rodriguez-Palacios, A.; Harding, A.; Menghini, P.; Himmelman, C.; Retuerto, M.; Nickerson, K.P.; Lam, M.; Croniger, C.M.; McLean, M.H.; Durum, S.K.; et al. The artificial sweetener Splenda promotes gut Proteobacteria, dysbiosis, and myeloperoxidase reactivity in Crohn’s disease-like ileitis. *Inflamm. Bowel Dis.* 2018, 24, 1005–1020. [CrossRef] [PubMed]

22. Suez, J.; Korem, T.; Zeevi, D.; Zilberman-Schapira, G.; Thais, C.A.; Maza, O.; Israeli, D.; Zmora, N.; Gilad, S.; Weinberger, A.; et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. *Nature* 2014, 514, 181–186. [CrossRef] [PubMed]

23. Catanzaro, J.R.; Strauss, J.D.; Bielecka, A.; Porto, A.F.; Lobo, F.M.; Urban, A.; Schofield, W.B.; Palm, N.W. IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of compensatory IgM. *Sci. Rep.* 2019, 9, 13574. [CrossRef] [PubMed]

24. Hussain, I.; Cher, G.L.Y.; Abid, M.A.; Abid, M.B. Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential. *Front. Immunol.* 2021, 12, 765965. [CrossRef] [PubMed]

25. Llorente, C.; Schnabl, B. The gut microbiota and liver disease. *Cell Mol. Gastroenterol. Hepatol.* 2015, 1, 275–284. [CrossRef] [PubMed]

26. Prg, C.W.; Lindén, S.K.; Glishenan, K.S.; Zoetendal, E.G.; McGweeney, C.S.; Sly, L.I.; McGuckin, M.A.; Florin, T.H. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by bacteria used in amylase production. *Am. J. Gastroenterol.* 2010, 105, 2420–2428. [CrossRef]

27. Chu, H.; Duan, Y.; Yang, L.; Schnabl, B. Small metabolites, possible big changes: A microbiota-centered view of non-alcoholic fatty liver disease. *Gut* 2019, 68, 359–370. [CrossRef]

28. Loomba, R.; Seguritan, V.; Li, W.; Long, T.; Klitgord, N.; Bhatt, A.; Dulai, P.; Caussy, C.; Bettencourt, R.; Highlander, S.K.; et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. *Cell Metab.* 2017, 25, 1054–1062.e5. [CrossRef]

29. Lee, G.; You, H.J.; Bajaj, J.S.; Joo, S.K.; Yu, J.; Park, S.; Kang, H.; Park, J.H.; Kim, J.H.; Lee, D.H.; et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. *Nat. Commun.* 2020, 11, 4982. [CrossRef]

30. Sokol, H.; Seksik, P.; Furet, J.P.; Firmesse, O.; Nion-Larmurier, I.; Beaugerie, L.; Cosnes, J.; Corthier, G.; Marteau, P.; Doré, J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. *Inflamm. Bowel Dis.* 2009, 15, 1183–1189. [CrossRef]

31. Rajilčić–Stojanović, M.; Belda, E.; Heilig, H.G.H.J.; Kajander, K.; Kekkonen, R.A.; Tims, S.; de Vos, W.M. Alterations of the human gut microbiome in liver cirrhosis. *Nature* 2014, 513, 500–504. [CrossRef]

32. Qin, N.; Yang, F.; Li, A.; Prifti, E.; Chen, Y.; Shao, L.; Guo, J.; Le Chatelier, E.; Yao, J.; Wu, L.; et al. Alterations of the human gut microbiome in liver cirrhosis. *Nature* 2014, 513, 59–64. [CrossRef] [PubMed]

33. Le Chatelier, E.; Nielsen, T.; Qin, J.; Prifti, E.; Hildebrand, F.; Falony, G.; Almeida, M.; Arumugam, M.; Batto, J.-M.; Kennedy, S. Richness of human gut microbiome correlates with metabolic markers. *Nature* 2013, 500, 541–546. [CrossRef]

34. Karlsson, F.H.; Tremaroli, V.; Nookaew, I.; Bergström, G.; Brehé, C.J.; Fagerberg, B.; Nielsen, J.; Bäckhed, F. Gut microbiome in European women with impaired, impaired and diabetic glucose control. *Nature* 2013, 498, 99–103. [CrossRef]

35. Aron-Wisnewsky, J.; Prifti, E.; Belda, E.; Ichou, F.; Kayser, B.D.; Dao, M.C.; Verger, E.O.; Hedjazi, L.; Bouillot, J.-L.; Chevallier, J.-M. Major microbiota dysbiosis in severe obesity: Fate after bariatric surgery. *Gut* 2019, 68, 70–82. [CrossRef] [PubMed]

36. Yang, A.M.; Inamine, T.; Hochrath, K.; Chen, P.; Wang, L.; Llorente, C.; Bluemel, S.; Hartmann, P.; Xu, J.; Koyama, Y.; et al. Intestinal fungi contribute to development of alcoholic liver disease. *J. Clin. Investig.* 2017, 127, 2829–2841. [CrossRef] [PubMed]
37. Frank, D.N.; St Amand, A.L.; Feldman, R.A.; Boedeker, E.C.; Harpaz, N.; Pace, N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc. Natl. Acad. Sci. USA* 2007, 104, 13780–13785. [CrossRef] [PubMed]

38. Gevers, D.; Kugathasan, S.; Denson, L.A.; Vázquez-Baeza, Y.; Van Treuren, W.; Ren, B.; Schwager, E.; Knights, D.; Song, S.J.; Yassour, M.; et al. The treatment-naive microbiome in new-onset Crohn’s disease. *Cell Host Microbe* 2014, 15, 382–392. [CrossRef]

39. Takahashi, K.; Nishida, A.; Fujimoto, T.; Fujii, M.; Shioya, M.; Imaeda, H.; Inatomi, O.; Bamba, S.; Andoh, A.; Sugimoto, M. Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn’s Disease. *Digestion* 2016, 93, 59–65. [CrossRef]

40. Loubinoux, J.; Bronowicki, J.P.; Pereira, I.A.; Mougenel, J.L.; Faou, A.E. Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. *FEMS Microbiol. Ecol.* 2002, 40, 107–112. [CrossRef]

41. Zinkevich, V.; Beech, I.B. Screening of sulfate-reducing bacteria in colonoscopy samples from healthy and colitic human gut mucosa. *FEMS Microbiol. Ecol.* 2000, 34, 147–155. [CrossRef] [PubMed]

42. Caussy, C.; Hsu, C.; Lo, M.T.; Liu, A.; Bettencourt, R.; Ajmera, V.H.; Bassirian, S.; Hooker, J.; Sy, E.; Richards, L.; et al. Link between gut-microbiome derived metabolite and shared gene-effects with hepatitis steatosis and fibrosis in NAFLD. *Hepatology* 2018, 68, 918–932. [CrossRef] [PubMed]

43. Hoyles, L.; Fernández-Real, J.M.; Federici, M.; Serino, M.; Abbott, J.; Charpentier, J.; Heymes, C.; Luque, J.L.; Anthony, E.; Barton, R.H.; et al. Molecular phenomics and metagenomics of hepatic steatosis in non-obese diabetic women. *Nat. Med.* 2018, 24, 1070–1080. [CrossRef] [PubMed]

44. Boursier, J.; Mueller, O.; Barret, M.; Machado, M.; Fizanne, L.; Araujo-Perez, F.; Guy, C.D.; Seed, P.C.; Rawls, J.F.; David, L.A.; et al. Screening of sulfate-reducing bacteria in colonoscopy samples from healthy and colitic human gut mucosa. *FEMS Microbiol. Ecol.* 2020, 28, 100436. [CrossRef] [PubMed]

45. Brandt, L.J.; Borody, T.J.; Campbell, J. Endoscopic fecal microbiota transplantation: “first-line” treatment for severe clostridium difficile infection. *J. Clin. Gastroenterol.* 2011, 45, 655–657. [CrossRef]

46. Hvas, C.L.; Bauwall, S.M.D.; Erikstrup, C. Faecal microbiota transplantation: A life-saving therapy challenged by commercial claims for exclusivity. *EClinicalMedicine* 2020, 24, 100436. [CrossRef]

47. Bauwall, S.M.D.; Lee, M.M.; Eriksen, M.K.; Mullish, B.H.; Marchesi, J.R.; Dahlérup, J.F.; Hvas, C.L. Faecal microbiota transplantation for recurrent Clostridiods difficile infection: An updated systematic review and meta-analysis. *EClinicalMedicine* 2020, 29–30, 100642. [CrossRef]

48. Lopetuso, L.R.; Ianiro, G.; Allegretti, J.R.; Bibbó, S.; Gasbarrini, A.; Scaldaferrì, F.; Cammarota, G. Fecal transplantation for ulcerative colitis: Current evidence and future applications. *Expert Opin. Biol. Ther.* 2020, 20, 343–351. [CrossRef]

49. Tian, H.; Ge, X.; Nie, Y.; Yang, L.; Ding, C.; McFarland, L.V.; Zhang, X.; Chen, Q.; Gong, J.; Li, N. Fecal microbiota transplantation in patients with slow-transit constipation: A randomized, clinical trial. *PLoS ONE* 2017, 12, e0171308. [CrossRef]

50. Cui, J.; Lin, Z.; Tian, H.; Yang, B.; Zhao, D.; Ye, C.; Li, N.; Qin, H.; Chen, Q. Long-Term Follow-Up Results of Fecal Microbiota Transplantation for Irritable Bowel Syndrome: A Single-Center, Retrospective Study. *Front. Med. (Lausanne)* 2021, 8, 710452. [CrossRef]

51. Bajaj, J.S.; Salzman, N.H.; Acharya, C.; Sterling, R.K.; White, M.B.; Gavis, E.A.; Fagan, A.; Hayward, M.; Holtz, M.L.; Matherly, S.; et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: A phase 1, randomized, placebo-controlled trial. *Hepatology* 2019, 70, 1690–1703. [CrossRef]

52. Philips, C.A.; Pande, A.; Shastry, S.M.; Jamwal, K.D.; Khillan, V.; Chandel, S.S.; Kumar, G.; Sharma, M.K.; Maiwall, R.; Jindal, A.; et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: A pilot study. *Hepatology* 2019, 69, 1690–1703. [CrossRef] [PubMed]

53. Schepici, G.; Silvestro, S.; Bramanti, P.; Mazzon, E. The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials. *Cell Transplant.* 2019, 28, 1507–1527. [CrossRef] [PubMed]

54. Xue, L.J.; Yang, X.Z.; Tong, Q.; Shen, P.; Ma, S.J.; Wu, S.N.; Zheng, J.L.; Wang, H.G. Fecal microbiota transplantation therapy for Parkinson’s disease: A preliminary study. *Medicine (Baltimore)* 2020, 99, e22035. [CrossRef]

55. Sanders, M.E.; Merenstein, D.J.; Reid, G.; Gibson, G.R.; Rastall, R.A. Probiotics and prebiotics in intestinal health and disease: From biology to the clinic. *Nat. Rev. Gastroenterol. Hepatol.* 2019, 16, 605–616. [CrossRef] [PubMed]

56. AlFaleh, K.; Anabrees, J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. *Cochrane Database Syst. Rev.* 2014, CD005496. [CrossRef]

57. Goldenberg, J.Z.; Lytvyn, L.; Steurich, J.; Parkin, P.; Mahant, S.; Johnston, B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. *Cochrane Database Syst. Rev.* 2015, CD004827. [CrossRef]

58. Mardini, H.E.; Grigorian, A.Y. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: A meta-analysis. *Inflamm. Bowel Dis.* 2014, 20, 1562–1567. [CrossRef]

59. Whorwell, P.J.; Altringer, L.; Moore, J.; Bond, Y.; Charbonneau, D.; O’Mahony, L.; Kiely, B.; Shanahan, F.; Quigley, E.M. Efficacy of Lactobacillus rhamnosus GG for treating acute gastroenteritis in children—A 2019 update. *Aliment. Pharmacol. Ther.* 2019, 49, 1376–1384. [CrossRef]
61. Wang, Z.; Roberts, A.B.; Buffa, J.A.; Levison, B.S.; Zhu, W.; Org, E.; Gu, X.; Huang, Y.; Zamanian-Daryoush, M.; Culley, M.K.; et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. *Cell* 2015, 163, 1585–1595. [CrossRef] [PubMed]

62. Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; Dugar, B.; Feldstein, A.E.; Britt, E.B.; Fu, X.; Chung, Y.M.; et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* 2011, 472, 57–63. [CrossRef] [PubMed]

63. Tang, W.H.; Wang, Z.; Levison, B.S.; Koeth, R.A.; Britt, E.B.; Fu, X.; Wu, Y.; Hazen, S.L. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N. Engl. J. Med.* 2013, 368, 1575–1584. [CrossRef] [PubMed]

64. Jaworska, K.; Hering, D.; Mosieniak, G.; Bielak-Zmijewska, A.; Pilz, M.; Konwerski, M.; Gasecka, A.; Kaplon-Cieslicka, A.; Filipiak, K.; Sikora, E.; et al. TMA, A Forgotten Uremic Toxin, but Not TMAO, Is Involved in Cardiovascular Pathology. *Toxins* 2019, 11, 490. [CrossRef]

65. Vinolo, M.A.; Rodrigues, H.G.; Festuccia, W.T.; Crisma, A.R.; Alves, V.S.; Martins, A.R.; Fiamoncini, J.; Hirabara, S.M.; Sato, F.T.; et al. Tributyrin attenuates obesity-associated inflammation and insulin resistance in high-fat-fed mice. *Am. J. Physiol. Endocrinol. Metab.* 2012, 303, E272–E282. [CrossRef]

66. Weitkunat, K.; Stuhlmann, C.; Postel, A.; Rumberger, S.; Fankhänel, M.; Wöting, A.; Petzke, K.J.; Gohlke, S.; Schulz, T.J.; Blaut, M.; et al. Short-chain fatty acids and inulin, but not guar gum, prevent diet-induced obesity and insulin resistance through differential mechanisms in mice. *Sci. Rep.* 2017, 7, 6109. [CrossRef]

67. Cipriani, S.; Mencarelli, A.; Palladino, G.; Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. *J. Lipid Res.* 2010, 51, 771–784. [CrossRef]

68. Fickert, P.; Fuchschieller, A.; Moustafa, T.; Wagner, M.; Zollner, G.; Halilbasic, E.; Stöger, U.; Arrese, M.; Pizarro, M.; Solís, N.; et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. *Am. J. Pathol.* 2009, 175, 2392–2405. [CrossRef]

69. Verbeke, L.; Farre, R.; Trebicka, J.; Komuta, M.; Roskams, T.; Klein, S.; Elst, I.V.; Windmolders, P.; Vanuytsel, T.; Nevens, F.; et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. *Hepatology* 2014, 59, 2286–2298. [CrossRef]

70. Neuschwander-Tetri, B.A.; Loomba, R.; Sanyal, A.J.; Lavine, J.E.; Van Natta, M.L.; Abdelmalek, M.F.; Chalasani, N.; Dasarathy, S.; Diehl, A.M.; Hameed, B.; et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. *Lancet* 2015, 385, 956–965. [CrossRef]

71. Harrison, S.A.; Rinella, M.E.; Abdelmalek, M.F.; Trotter, J.F.; Paredes, A.H.; Arnold, H.L.; Kugelmas, M.; Bashir, M.R.; Jaros, M.J.; Ling, L.; et al. NGS282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* 2018, 391, 1174–1185. [CrossRef]

72. Kostic, A.D.; Gevers, D.; Siljander, H.; Vatanen, T.; Hyötyläinen, T.; Hämäläinen, A.M.; Peet, A.; Tillmann, V.; Pöö, P.; Mattila, I.; et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. *Cell Host Microbe* 2015, 17, 260–273. [CrossRef] [PubMed]

73. Schepersjans, F.; Aho, V.; Pereira, P.A.; Koskinen, K.; Paulin, L.; Pekkonen, E.; Haapaniemi, E.; Kaakkola, S.; Eerola-Rautio, J.; Pohja, M.; et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. *Mov. Disord.* 2015, 30, 350–358. [CrossRef] [PubMed]